Indivior prices upsized $450M convertible notes at 0.625% due 2031

Indivior Pharmaceuticals, Inc.

Principal amount $450M (upsized from $400M); 0.625% interest, matures March 15, 2031.
Net proceeds ~$437.7M (~$486.4M if initial purchasers' option fully exercised).
~$239M of proceeds plus $102M cash used to repay term loan and revolver.
Concurrent $75M repurchase of ~2.4M shares from note purchasers at market price.
Initial conversion price ~$41.66/share, a 35% premium over March 12 closing price.

item 8.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001625297-26-000012
form_type: 8-K
ticker: INDV
cik: 0001625297
company_name: Indivior Pharmaceuticals, Inc.
filed_at: 2026-03-13T23:59:59+00:00
discovered_at: 2026-05-14T18:02:35.674324+00:00
generated_at: 2026-05-15T12:36:40.820850+00:00
sec_items: ["8.01", "9.01"]
event_type: debt
sentiment: neutral
materiality_score: 0.7
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001625297-26-000012
json_url: https://secwatch.observer/filing/0001625297-26-000012.json
markdown_url: https://secwatch.observer/filing/0001625297-26-000012.md
text_url: https://secwatch.observer/filing/0001625297-26-000012.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1625297/000162529726000012/0001625297-26-000012-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1625297/000162529726000012/indv-20260312.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001625297-26-000012

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.